Ann: Paradigm Secures Ethics Approval for Phase 3 Trial, page-53

Edski, a very good evening to you. Nice to hear from you - its been too long. Yeah I agree, its not just about what we have, its also about what we do not have!

It would make sense to get on this from a front foot sense but I reckon more will be receptive once they can actually source the product from their local dispensaries. Yes it is all about how our product works but also how to circumvent the products out there that are full of nasties to which the average patient has no alternatives. But as you say, its also about educating the patient, why are we different and what is our goal? There is benefit also in covering HOW it works and WHY it works. Why is it better than anything else out there, what are the advantages to the patient? Why should the patient consider trying iPPS.

There is a lot of merit of starting our campaign earlier, specially as we draw closer to a Phase 3 readout. This doesn't just imply the end of the study sometime in 2027, a point, like a few others have made, around interim is also a great opportunity. That milestone isn't all that far away potentially. Maybe a little more than a year from now. One thing we do know is how consistent our data has been across the varying studies and indications, not just from PAR but from other researchers. I also like their website, HopeForOA. Considering we are in the recruiting phase, it's a nice professional way to broach the few patients we need for P3.

I believe that PAR, once they form alliances with BP later on, will not just be merely a dispensing type of co. I would like to think they will educate a lot of patients through varying campaigns to inform patients about more healthy living, bringing down inflammation as a result of our naturally based drug. Zilosul might be a one hit wonder in many cases but it should also be about education of the patient encouraging them to continue to maintain good exercise regimes and well being for the ultimate benefit of the patient. I also see a close relationship between the company and the Doc's associations and Doc's themselves. I feel there would be a LOT to be gained from patient feedback and Doc feedback to the co. No doubt there will be a lot of Off-Labelling that occurs and this kind of data would be invaluable to the co and to us shareholders.

Zilosul in many, many cases will take away the pain and set the body on a path of repair and in some cases regeneration, but it has to be the patient that nurtures these new pathways for themselves.